Business Development Consulting
EXPERT PHARMA PARTNERSHIPS
WELCOME TO BUSINESS DEVELOPMENT PHARMA CONSULTING
The pharmaceutical market has faced great challenges, the world also encounters new situations as pandemics and social, structural and climatic changes. In a view of this, the pharmaceutical industry has been finding great dilemmas: how to grow sustainably? How to maintain profitability? How to help the world with new pathologies? Given this, the answer does not always come from within, we need to unite stakeholders, available information and the network of contacts to suppress demands and maintain our organization growing.
How to do this? We are here to help you find and make moves to keep your corporation in the game.
With over 17 years of experience in the pharmaceutical industry in the area of new business, new products, project and portfolio management, a new phase has started since 2017 with a new form of customized consultancy work...
PROFILE
CARLOS NORIO KAMIYA
Business Development & Project Management Senior Executive
Executive with experience in large international pharmaceutical companies, leaders in their segments, structured new business and project departments, built product pipelines that represent more than 350 million euros in the areas of RX, OTC, Specialty and Generics. Currently based in Switzerland, the center of Europe and home to dozens of pharmaceutical companies.
NEWS & PRESS
SOme main news of pharmaceutical and healthcare industry
25, November 2020
The Commission has today adopted a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU's pharmaceutical industry. The Strategy will allow Europe to cover its pharmaceutical needs, including in times of crisis, through robust supply chains
14, December 2020
COVID-19 has had little positive impact on perceptions of pharmaceutical companies
A report launched today by pharmaceutical company Takeda UK reveals that, despite heightened public and media attention on the industry’s efforts to develop vaccines and treatments, the COVID-19 pandemic has had little positive impact on perceptions of pharmaceutical companies
